-
公开(公告)号：EP4276111A1
公开(公告)日：2023-11-15
申请号：EP22736575.6
申请日：2022-01-07
发明人： LIU, Yang , ZHANG, Ruijing , FAN, Fei , LI, Xiaochun , YU, Lu , LIU, Jiawang , LEE, Kyoung Woo
IPC分类号： C07K16/28 , A61P35/00 , A61K39/395 , C12N15/13
摘要： Provided are an antibody specifically binding to 4-1BB and an antigen-binding fragment thereof. The antibody specifically binding to 4-1BB and the antigen-binding fragment of the antibody have high specificity, and after being binded to an antigen, the antibody and the antigen-binding fragment thereof can enhance an immune killing function of T cells, can induce activation of immune cells and promote secretion of cytokines, and can significantly inhibit the growth of tumors in the body.
-
公开(公告)号：EP4196483A1
公开(公告)日：2023-06-21
申请号：EP21856309.6
申请日：2021-05-20
发明人： JUNG, Seung Hyun , HONG, Dong Jin , HWANG, Ji Young , KIM, Seo Hee , PARK, So Min , MAH, Shin Mee , AHN, Young Gil
IPC分类号： C07D491/056 , A61K31/4738 , A61P35/00
-
公开(公告)号：EP3929199A1
公开(公告)日：2021-12-29
申请号：EP20759257.7
申请日：2020-02-19
发明人： HONG, Dong Jin , JUNG, Seung Hyun , PARK, Chang Hee , KIM, Seo Hee , HWANG, Ji Young , AHN, Young Gil
IPC分类号： C07D491/04 , A61K31/4743 , A61P35/00
摘要： The present disclosure relates to novel heterotricyclic derivative compounds and the use thereof, and more particularly, to novel heterotricyclic derivative compounds having inhibitory activity against EZH1 (enhancer of zeste homolog 1) and/or EZH2 (enhancer of zeste homolog 2) activity, pharmaceutically acceptable salts thereof, or pharmaceutical compositions containing these compounds.
-
4.发明公开
公开(公告)号：EP3735429A1
公开(公告)日：2020-11-11
申请号：EP19751154.6
申请日：2019-02-08
发明人： LIU, Jiawang , SONG, Nanmeng , YANG, Yaping , KIM, Maeng Sup , YAN, Yao , YIN, Qingqing
-
5.发明公开COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES 审中-公开VERBINDUNG ZUR HEMMUNG VONAKTIVITÄTENVON BTK- UND / ODER JAK3-KINASEN
公开(公告)号：EP3048105A4
公开(公告)日：2017-05-17
申请号：EP14846251
申请日：2014-09-18
发明人： LIU JINMING , CHA MI YOUNG , LI GONG , LI ZHANMEI , QIU HONGJUAN , KIM MAENGSUP
IPC分类号： C07D487/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61P1/00 , A61P7/02 , A61P11/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/02 , C07D491/048 , C07D495/04 , C07D519/00
CPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D487/04 , C07D491/048 , C07D519/00 , A61K2300/00
-
6.发明公开COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES 审中-公开VERBINDUNG ZUR HEMMUNG VONAKTIVITÄTENVON BTK- UND / ODER JAK3-KINASEN
公开(公告)号：EP3048105A1
公开(公告)日：2016-07-27
申请号：EP14846251.8
申请日：2014-09-18
发明人： LIU, Jinming , CHA, Mi Young , LI, Gong , LI, Zhanmei , QIU, Hongjuan , KIM, Maengsup
IPC分类号： C07D487/04 , C07D491/048 , C07D495/04 , C07D519/00 , A61K31/53 , A61K31/519 , A61K31/5377 , A61P37/02 , A61P29/00 , A61P7/02 , A61P35/00 , A61P19/02 , A61P11/00 , A61P17/06 , A61P1/00
CPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D487/04 , C07D491/048 , C07D519/00 , A61K2300/00
摘要： The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula ( I ).
摘要翻译： 本发明涉及抑制Bruton酪氨酸激酶（BTK）和/或Janus激酶3（JAK3）的活性的化合物，该化合物的药物组合物，其药物应用，使用该化合物抑制活性的方法 BTK和/或JAK3，以及在哺乳动物（特别是人）中用于治疗和/或预防BTK和/或JAK3介导的疾病或病症的方法。 该化合物由结构式（I）表示。
-
7.发明公开NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT 审中-公开新嘧啶和药物组合物，作为ACTIVE
公开(公告)号：EP2738174A4
公开(公告)日：2014-12-17
申请号：EP12817633
申请日：2012-06-29
发明人： PARK CHUL HYUN , KIM WON JEOUNG , JUNG YOUNG HEE , KIM NAM DU , CHANG YOUNG KIL , KIM MAENG SUP
IPC分类号： C07D495/04 , A61K31/519 , A61P3/00 , A61P3/04 , A61P3/10 , A61P9/00 , C07D487/04
CPC分类号： C07D495/04 , C07D487/04
-
8.发明公开A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE 有权药物组合物，癌的干扰素α缀合物的治疗
公开(公告)号：EP2753348A1
公开(公告)日：2014-07-16
申请号：EP12830783.2
申请日：2012-09-05
发明人： JUNG, Sung Youb , WOO, Young Eun , LIM, Se Young , CHOI, In Young , LEE, Jae Ho , KWON, Se Chang , MOON, Sung Hwan , LIU, Jiawang
IPC分类号： A61K38/21 , A61K39/395 , A61K47/48 , A61K47/30 , A61P35/00
摘要： A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
-
9.发明公开IgG Fc fragment for a drug carrier and method for the preparation thereof 有权IgG-Fc-FragmentfüreinenArzneimittelträgerund Verfahren zu dessen Herstellung
公开(公告)号：EP2256134A1
公开(公告)日：2010-12-01
申请号：EP10009129.7
申请日：2004-11-13
发明人： Jung, Sung Youb , Kim, Jin Sun , Yang, Geun Hee , Kwon, Se Chang , Lee, Gwan Sun
CPC分类号： A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
摘要翻译： 公开了可用作药物载体的IgG Fc片段。 此外，本发明公开了表达IgG Fc片段的重组载体，用重组载体转化的转化体，以及制备IgG Fc片段的方法，包括培养转化体。 当缀合到某种药物时，IgG Fc片段改善药物作用的体内持续时间并使药物的体内活性降低最小化。
-
10.发明公开INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED 审中-公开胰岛素肽修饰N-端氨基酸衍生物
公开(公告)号：EP2176289A4
公开(公告)日：2010-10-27
申请号：EP08778827
申请日：2008-07-16
发明人： SONG DAE HAE , LIM CHANG KI , KIM YOUNG HOON , KWON SE CHANG , LEE GWAN SUN , BAE SUNG MIN , JUNG SUNG YOUB
CPC分类号： C07K14/46 , A61K38/26 , C07K14/57563 , C07K14/605
-
-
-
-
-
-
-
-
-
搜索结果
71 条记录 (耗时 0.022 秒)
